Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Oct 30, 2026

Transcripta Bio Announces Research Collaboration to Advance Discovery of New Treatments for Autism Spectrum Disorder

PALO ALTO, Calif.--(BUSINESS WIRE)--Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced a know-how agreement with Mayo Clinic focused on the molecular characterization of autism spectrum disorder (ASD). The collaboration seeks to combine Mayo Clinic's clinical genomics and neurodevelopmental expertise with Transcripta Bio's transcriptomic drug discovery platform to investigate the molecular mechanisms underlying ASD and identi
Press release cover image

Oct 29, 2026

Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction

Etcelera unites the platform technologies of Cellarity, Etiome, and Empress Therapeutics with Flagship Pioneering's proprietary AI capabilities to scale causal intelligence in human biologyVeteran CEO and accomplished company builder Ad Rawcliffe to lead new entityCAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the formation of Etcelera, a company created by the merger of the platforms
Press release cover image

Oct 29, 2026

ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline

Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF)Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery platform and the advancement of a focused pipeline of small molecules against high-value, historically difficult-to-drug protein-protein interactions and transcription factorsSeasoned biotech executive and investor Morten Graugaard, Co-founder and CBO of Orbis Medicines, appointed
Press release cover image

Oct 29, 2026

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies

Enables high-throughput assessment of thousands of antibodies per day to support AI/ML-driven discovery workflowsTurnaround time starting in as little as five daysSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG w
Press release cover image

Oct 29, 2026

Carterra and Grenova Robotics Integrate Carterra Vega™ with KX2 Collaborative Robot to Create Automated HT-SPR Work Cell

Plug-and-play automation supports high-throughput screening for biologics and small molecules with extended walkaway capability.COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--#Partnership--Carterra and Grenova Robotics today announced the integration of Carterra Vega™ high-throughput surface plasmon resonance (HT-SPR™) platform with Grenova Robotics’ KX2 collaborative robot to create an automated work cell for drug discovery laboratories. The integrated system enables researchers to screen more than
Press release cover image

Oct 29, 2026

Caravel Bio Secures $1.2M NSF Phase II Grant to Scale the Data Engine Behind Its Full-Stack Protein Engineering Platform

The grant funds the next chapter for Caravel's full-stack platform—built to create value for all proteins—while scaling machine learning datasets and real-world pilots for existing customers. Michał Jastrzębski also joins as CTO to lead the company's AI-driven protein engineering work.PORTLAND, Ore., Oct. 28, 2026 /PRNewswire/ -- Caravel Bio, the company creating new high-performance systems for discovering, engineering, and manufacturing biomolecules, has been awarded a $1,246,984 Small Busines
Press release cover image

Oct 28, 2026

Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of researchVANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis
A laboratory flask with green liquid on a workbench in a dimly lit lab

Oct 27, 2026

Early progress on accelerating drug development with Claude

Anthropic's life sciences team is making strides in accelerating drug development through innovative partnerships and AI integration.Over the past few months, Anthropic has collaborated with six organizations—including BigHat Biosciences and Bristol Myers Squibb—to enhance drug discovery processes. Their approach involves leveraging AI, specifically Claude, across various stages of drug development, from initial research to regulatory filings. The team has identified that the challenges in drug
A vaccine vial on a laboratory countertop in a dimly lit lab setting.

Oct 27, 2026

NEC joins EU AI vaccine project for pandemic readiness

NEC has joined the EU-funded PREPAIR VAC initiative, focusing on enhancing pandemic preparedness through AI-driven vaccine design.The PREPAIR VAC project, backed by Horizon Europe, aims to streamline vaccine development in response to emerging infectious diseases. With a budget of approximately €6.5 million, the four-year initiative includes NEC OncoImmunity, which will lead efforts in antigen prediction and AI-based vaccine design. The consortium, coordinated by the European Vaccine Initiative,
A minimalist representation of a clinical trial document and an AI agent.

Oct 26, 2026

Virtual biotech deploys 37,000 AI agents across drug discovery

A virtual biotech company has harnessed the power of 37,000 AI agents to revolutionize drug discovery, analyzing around 50,000 clinical trials to identify key molecular features that enhance drug development outcomes.Developed by researchers at Stanford Medicine, this innovative project operates like a traditional biotech firm, with specialized AI agents functioning in roles akin to those of human researchers. Each agent is tasked with analyzing specific clinical trials, significantly reducing t
Press release cover image

Oct 26, 2026

Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline

Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors.Th
Press release cover image

Oct 26, 2026

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreementPathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapiesBMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform,